ArticleChina CDC weekly2026
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To address the escalating public health threat of hypervirulent and antibiotic-resistant Methods: KPGD integrates 75,987 genome assemblies from 122 countries with standardized annotations of serotypes, sequence types, antibiotic resistance genes (ARGs), virulence factors (VFs), and mobile genetic elements (MGEs). The platform offers interactive visualization modules and integrated analytical tools that enable real-time epidemiological monitoring and one-stop genomic analysis, thereby supporting global efforts to track the dissemination of resistant and hypervirulent KP (HvKp) and to inform infection control and antimicrobial stewardship strategies. Results: Longitudinal analyses revealed that the emergence of HvKp is driven by the sustained expansion of carbapenem-resistant high-risk lineages under selection pressure from restricted, higher-tier antibiotics. Conjugative ARG-bearing plasmids carrying key resistance determinants largely mediate this expansion. In contrast, selection by first-line, narrower-spectrum antibiotics appears to favor the dissemination of virulence plasmids (predominantly IncFIB types) as a compensatory mechanism to offset resistance-associated fitness costs. Conclusion: These findings collectively underscore the need for surveillance systems that simultaneously monitor high-risk lineages and the dissemination of ARGs and VFs - particularly via self-transmissible plasmids - to better understand and anticipate bacterial adaptation under diverse antibiotic pressures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.